Fiveprime - geht da noch was?

Zahlen für Q3/20

• Umsatz 2 Mio. $
  
• Verlust 26 Mio. $
  
• Cash 113 Mio. $
  
• MK 177 Mio. $
  
• Top-Line Phase 2 FIGHT data on track to be announced in 2020
  

Clinical Pipeline:

Bemarituzumab (anti-FGFR2b) is a first-in-class isoform-selective antibody with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) being studied in the FIGHT trial as a targeted therapy for front-line FGFR2b+/HER2- gastric and gastroesophageal junction (GEJ) cancer.

• The company expects to report top-line data before year end from the double-blind Phase 2 FIGHT study where all 155 patients receive standard mFOLFOX6 chemotherapy and are randomized to receive bemarituzumab or placebo.
  
• The primary endpoint of the Phase 2 FIGHT trial is progression-free survival (PFS), and a secondary endpoint is overall survival (OS).
  

investor.fiveprime.com/news-releases/...-quarter-2020-results

142 Mio. $ Offering

Das ist ein 1A Offering, gutes Pricing und sogar noch upsized.

• 7,2 Mio. neue Aktien zu je 21$
  
• Option auf weitere 15%
  

"Five Prime plans to use the net proceeds of the offering, together with other available funds, to fund ongoing clinical development of bemarituzumab and FPT155, to advance FPA157 through preclinical and into clinical development, to advance its late-stage research programs and for working capital and general corporate purposes."

investor.fiveprime.com/news-releases/...lic-offering-common-0

Amgen übernimmt FPRX in einem 1,9 Mrd. $ Deal

• 38$ Cash pro Aktie
  
• AMGN zahlt 78% Premium
  

www.fiercebiotech.com/biotech/...herapeutics-a-1-9b-cash-deal